Singapore, 7th November 2008 – Maccine Pte Ltd, the pre-clinical contract research group, announced the appointment of Leigh Berryman to the position of Chief Executive Officer of Maccine Pte Ltd (and subsidiary companies) with effect from 1 December 2008.
Leigh Berryman is an accredited toxicologist and certified-GLP professional with over 32 years experience in the industry (24 years in contract research with a focus on serving the biotech industry). He has worked internationally in various senior management roles across Europe and North America including positions with Huntingdon Life Sciences, Sterling Drug, Notox and Shell Oil. Leigh founded LAB Research in 1998 and left following it’s IPO in 2006.
“We are delighted to have been able to attract Leigh into Maccine”, said Dr Angus Bell, Chairman of Maccine’s Board of Directors, “His combination of scientific knowledge and experience, coupled with a proven track record of successfully growing preclinical CRO businesses will enable us to greatly accelerate our plans to bring Maccine to the forefront of world class Contract Research Organizations”.
“I am equally as delighted”, replied Leigh, “Maccine has established itself as a leader in the translational medicine space with a portfolio of high level pre-clinical efficacy models. With the pharmaceutical industry’s greatly increased focus on picking winning drugs earlier in the drug development cycle, and interest in large molecule development as biopharmaceutical moieties, I believe Maccine is positioned for significant immediate growth. I am very enthusiastic about bringing the specialized services that Maccine can offer to our valued clients”.
About Maccine:
Maccine Pte Ltd is a Singapore based pre-clinical contract research organization providing innovative discovery support and quality safety assessment services to the global pharmaceutical and biotechnology industry.
